Sign Up for Free!

Continue Analyzing the page and more.

Continue with Google

Already have an Account? Log In

The Trial has ended

Continue Analyzing the page and more.

Upgrade to Pro
Home Daily Intelligence Tracker
    • Plans Blog Contact
    Medicenna Therapeutics Corp logo
    MDNA

    Medicenna Therapeutics Corp

    MaveScore 10 Low model confidence
    Last Price US$0.16 As of Updating
    Market Cap US$10.9m Company size context
    7D Performance -37.33% Past 7 days
    1Y Performance -83.98% Past 12 months
    Model Rating
    Historical model output for research review

    Fundamental data date

    Updating

    Refreshing

    Market price date

    Updating

    Refreshing

    Coverage

    7/16

    9 missing model inputs

    Data quality

    Limited

    Limited stored snapshot

    Transparent research score

    Why the model scores this stock

    MaveScore is a research prioritization score from 0 to 100. It is historical model output for watchlist review, not personalized financial advice.

    MaveScore 10 Low confidence

    Stored data quality

    Freshness and coverage checks

    Mavefund is missing enough stored company inputs that this score should be treated as preliminary research only.

    7/16 Limited stored snapshot

    Quality

    Quality score blends the latest weighted model rank with underlying profitability and dilution ranks.

    10/35 Weak

    Financial Strength

    Financial strength needs live profitability and cash-flow fields.

    0/25 Needs Data

    Valuation Support

    Valuation needs price plus per-share earnings, cash-flow, or book-value inputs.

    0/15 Needs Data

    Momentum

    Momentum needs recent 3-month or 6-month price-change data.

    0/15 Needs Data

    Shareholder Alignment

    Shareholder alignment rewards less dilutive share behavior and enough size for liquid research coverage.

    0/10 Weak

    Positive model output

    More live company inputs are needed before positive research signals can be surfaced.

    Research risks to review

    • Quality score blends the latest weighted model rank with underlying profitability and dilution ranks.
    • Financial strength needs live profitability and cash-flow fields.
    • Valuation needs price plus per-share earnings, cash-flow, or book-value inputs.

    MaveScore uses historical model inputs, stored company fundamentals, and stored price context for research support only. Review missing inputs and business-specific risks before acting. Missing inputs right now include return on equity, net margin, gross margin, free cash flow per share, book value per share, earnings per share, latest price, 3-month price change, 6-month price change.

    Overview Price History News Competitors Earnings per Share Return on Equity Net Margin Share Buyback Leverage Financial Ratio
    Dashboard Funda..tals Deep..lue Prediction Screener Map

    Medicenna Therapeutics Corp Overview

    Industry: Biotechnology & Medical Research

    Sector: Healthcare

    Medicenna Therapeutics Corp., an immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer and other diseases. Its lead product is MDNA55, an interleukin- 4 (IL-4) EC that has completed Phase IIb clinical trial for the treatment of recurrent glioblastoma, as well as preclinical and clinical development stages for the treatment of other brain and non-brain tumors. The company also develops MDNA11, an enhanced version of IL-2 to activate and proliferate the immune cells needed to fight cancer; MDNA209, an IL-2 antagonist for autoimmune diseases, such as multiple sclerosis and graft versus host disease; MDNA413, a dual IL-4/IL-13 antagonist to treat cancer immunotherapies; and MDNA132, an IL-13 Superkine for solid tumors. In addition, it provides BiSKITs platform to develop designer Superkines by fusing them to other proteins, antibodies, cytokines, or other Superkines. The company is headquartered in Toronto, Canada.

    Medicenna Therapeutics Corp is evaluated using Mavefund's quality framework: growing earnings, durable profit margins, conservative leverage, strong return on equity, and disciplined share repurchases.

    Score

    Price History & Performance

    Review Medicenna Therapeutics Corp in context before unlocking the interactive price chart, financial overlays, and downloadable ratio tables.

    Recent News



    Medicenna Therapeutics Corp Competitors

    Medicenna Therapeutics Corp operates in the Biotechnology & Medical Research industry within the Healthcare sector. Unlock the full page to compare peer rankings, valuation quality, profitability, leverage, and growth trends.

    Earnings Per Share

    EPS quality is one of the core Mavefund signals. Sign up to continue into the detailed EPS, ROE, margin, share buyback, leverage, and financial ratio analysis.

    Continue the analysis

    Sign up to unlock ROE, net margin, share buyback, leverage, financial ratios, peer charts, and downloads.

    View plans
    Ticker Image

    Medicenna Therapeutics Corp

    US$0.16

    US$10.9m

    -37.33%

    -83.98%